HALLUCINATIONS IN PARKINSON DISEASE - NEUROPSYCHOLOGICAL STUDY

被引:29
作者
MECO, G
BONIFATI, V
CUSIMANO, G
FABRIZIO, E
VANACORE, N
机构
[1] Dipartimento di Scienze Neurologiche, Università 'La Sapienza', Roma, 00185
来源
ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES | 1990年 / 11卷 / 04期
关键词
dementia; hallucinations; Parkinson disease;
D O I
10.1007/BF02335940
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Hallucinations occur fairly frequently in the course of the pharmacological treatment of Parkinson disease. Our aim in this study was to assess first the relation between hallucinations and mental deterioration and second the correlation between the perception disorder and the profile on the Minnesota Multiphasic Personality Inventory (MMPI). Of 304 parkinsonian subjects followed as outpatients at our center 27 (8.88%) had had hallucinations and 17 of these presented marked cognitive deficits (Mini Mental State <18) (62.9%) compared with 32 of the other 277 patients (11.5%) (X2=55.16, p<0.0001). A group of 9 patients who had had hallucinations and 10 controls who had not, all free from marked cognitive deficits, were assessed on the Luria-Nebraska Neuropsychological Battery (LNNB) and on the MMPI. The two groups did not differ significantly in respect of the LNNB but did in respect of the MMPI scales. On this evidence the frequency of mental deterioration is significantly higher in patients who have hallucinated. We discuss the meaning of the MMPI differences both from the biochemical angle and from that of personality factors. These data suggest that the MMPI might be useful for predicting hallucinations in undeteriorated parkinsonian patients on pharmacological therapy. © 1990 Masson Italia periodici s.r.l.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 26 条
[1]  
Birkmayer W., Neumayer E., Die moderne medikamentose Behandlung des Parkinsonismus, Z. Neurol., 202, pp. 257-280, (1972)
[2]  
Boller F., Mizutani T., Roessmann U., Et al., Parkinson's disease, dementia and Alzheimer disease: clinicopathological correlations, Ann Neurol, 7, pp. 329-355, (1980)
[3]  
Boller F., Passafiume D., Keefe N.C., Et al., Visuospatial impairment in Parkinson's disease: role of perceptual and motor factors, Arch Neurol, Chicago, 41, pp. 485-490, (1984)
[4]  
Casacchia M., Meco G., Corona R., Cappellini R., Gli effetti psichiatrici durante la terapia del morbo di Parkinson. Considerazioni cliniche e prospettive terapeutiche, Atti IV Riunione L.I.M.P.E., (Cagliari 1977), pp. 209-219, (1978)
[5]  
Celesia G.G., Barr A.N., Psychosis and other psychiatric manifestations of levodopa therapy, Arch Neurol, 23, pp. 193-200, (1970)
[6]  
Critchley P., Perez F.G., Quinn N., Coleman R., Parkers D., Marsden C.D., Psychosis and lisuride pump, Lancet, 2, (1986)
[7]  
Dahlstrom W.G.G., Welsh G.S., Dahlstrom O.E., An MMPI handbook. Vol. 10: Clinical Interpretation, (1972)
[8]  
De Smet Y., Ruberg M., Serdaru M., Et al., Confusion, dementia and anticholinergics in Parkinson's disease, J Neurol Neurosurg Psychiatry, 45, pp. 1161-1164, (1982)
[9]  
Dubois B., Danze' F., Pillon B., Cusimano G., Et al., Cholinergic-dependent cognitive deficits in Parkinson's disease, Ann Neurol, 22, pp. 26-30, (1987)
[10]  
Flowers K.A., Pearce I., Pearce J.M.S., Recognition memory in Parkinson's disease, J Neurol Neurosurg Psychiatry, 47, pp. 1174-1181, (1984)